These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20425477)

  • 1. Beyond acid suppression: new pharmacologic approaches for treatment of GERD.
    Kuo P; Holloway RH
    Curr Gastroenterol Rep; 2010 Jun; 12(3):175-80. PubMed ID: 20425477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
    Lehmann A; Antonsson M; Holmberg AA; Blackshaw LA; Brändén L; Bräuner-Osborne H; Christiansen B; Dent J; Elebring T; Jacobson BM; Jensen J; Mattsson JP; Nilsson K; Oja SS; Page AJ; Saransaari P; von Unge S
    J Pharmacol Exp Ther; 2009 Nov; 331(2):504-12. PubMed ID: 19648470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel treatments of GERD: focus on the lower esophageal sphincter.
    Lehmann A
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():103-10. PubMed ID: 18924449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs.
    Brändén L; Fredriksson A; Harring E; Jensen J; Lehmann A
    Eur J Pharmacol; 2010 May; 634(1-3):138-41. PubMed ID: 20176012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational gastrointestinal pharmacology in the 21st century: 'the lesogaberan story'.
    Boeckxstaens GE; Denison H; Jensen JM; Lehmann A; Ruth M
    Curr Opin Pharmacol; 2011 Dec; 11(6):630-3. PubMed ID: 22036168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lesogaberan, a GABA(B) agonist for the potential treatment of gastroesophageal reflux disease.
    Bredenoord AJ
    IDrugs; 2009 Sep; 12(9):576-84. PubMed ID: 19697277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands.
    Frisby CL; Mattsson JP; Jensen JM; Lehmann A; Dent J; Blackshaw LA
    Gastroenterology; 2005 Sep; 129(3):995-1004. PubMed ID: 16143137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reflux inhibitors: a new approach for GERD?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):685-9. PubMed ID: 18771751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of gastro-esophageal reflux disease: the new kids to block.
    Blondeau K
    Neurogastroenterol Motil; 2010 Aug; 22(8):836-40. PubMed ID: 20663054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABAB receptors as drug targets to treat gastroesophageal reflux disease.
    Lehmann A
    Pharmacol Ther; 2009 Jun; 122(3):239-45. PubMed ID: 19303900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease.
    Boeckxstaens GE; Beaumont H; Mertens V; Denison H; Ruth M; Adler J; Silberg DG; Sifrim D
    Gastroenterology; 2010 Aug; 139(2):409-17. PubMed ID: 20451523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.
    Rouzade-Dominguez ML; Pezous N; David OJ; Tutuian R; Bruley des Varannes S; Tack J; Malfertheiner P; Allescher HD; Ufer M; Rühl A
    Neurogastroenterol Motil; 2017 Aug; 29(8):. PubMed ID: 28337838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
    Alstermark C; Amin K; Dinn SR; Elebring T; Fjellström O; Fitzpatrick K; Geiss WB; Gottfries J; Guzzo PR; Harding JP; Holmén A; Kothare M; Lehmann A; Mattsson JP; Nilsson K; Sundén G; Swanson M; von Unge S; Woo AM; Wyle MJ; Zheng X
    J Med Chem; 2008 Jul; 51(14):4315-20. PubMed ID: 18578471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog.
    Lehmann A; Hansson-Brändén L; Kärrberg L
    Eur J Pharmacol; 2000 Sep; 403(1-2):163-7. PubMed ID: 10969158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatments of GERD: the old and new.
    Vela MF
    Gastroenterol Clin North Am; 2014 Mar; 43(1):121-33. PubMed ID: 24503363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study.
    Beaumont H; Smout A; Aanen M; Rydholm H; Lei A; Lehmann A; Ruth M; Boeckxstaens G
    Aliment Pharmacol Ther; 2009 Nov; 30(9):937-46. PubMed ID: 19650825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients?
    Kahrilas PJ; Boeckxstaens G
    Gut; 2012 Oct; 61(10):1501-9. PubMed ID: 22684485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel?
    Wise J; Conklin JL
    Curr Gastroenterol Rep; 2004 Jun; 6(3):213-9. PubMed ID: 15128488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is nonacid reflux disease?
    Storr MA
    Can J Gastroenterol; 2011 Jan; 25(1):35-8. PubMed ID: 21258666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of GORD. Emerging therapeutic targets and concepts.
    Zerbib F
    Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):937-46. PubMed ID: 21126705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.